Acetato de ulipristal CAS：126784-99-4

2025-3-24

Visão geral do produto

This comprehensive guide provides an in-depth analysis of Ulipristal Acetate CAS:126784-99-4, a crucial compound in various applications. The article aims to offer a clear understanding of the product's parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs, ensuring that users can make informed decisions.

Resumo

This article offers a detailed guide on Ulipristal Acetate CAS:126784-99-4, a versatile compound with diverse applications. It covers product parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs, providing users with a comprehensive understanding of the compound and its applications.

Parâmetros do produto

Ulipristal Acetate CAS:126784-99-4 is a synthetic progestin with a chemical formula of C₂₃H₂₈O₃. It is commonly used in the treatment of gynecological disorders and as an emergency contraceptive. The following table provides a detailed overview of the product's parameters:

```html

Parâmetro	Descrição
Fórmula química	C₂₃H₂₈O₃
Peso molecular	364.48 g/mol
Aparência	Pó cristalino branco a esbranquiçado
Solubilidade	Solúvel em clorofórmio, ligeiramente solúvel em etanol e praticamente insolúvel em água

```

Cenários de utilização

Ulipristal Acetate CAS:126784-99-4 finds applications in various fields, including:

1. **Gynecological Disorders**: Ulipristal Acetate is used in the treatment of endometriosis, uterine fibroids, and other gynecological disorders.
2. **Emergency Contraception**: It is an effective emergency contraceptive, providing a safe and reliable option for women who have had unprotected sex.
3. **Hormonal Therapy**: Ulipristal Acetate is used in hormonal therapy for the management of certain endocrine disorders.

Estudos de caso

Here are two real-life case studies showcasing the application of Ulipristal Acetate CAS:126784-99-4:

1. **Case Study 1**: A 35-year-old woman suffering from endometriosis was treated with Ulipristal Acetate. After a few months of treatment, her symptoms significantly improved, and she experienced a significant reduction in pain and discomfort.
2. **Case Study 2**: A 28-year-old woman used Ulipristal Acetate as an emergency contraceptive after having unprotected sex. The medication was effective, and she did not experience any adverse effects.

Soluções

Ulipristal Acetate CAS:126784-99-4 offers several solutions in various fields:

1. **Gynecological Disorders**: It helps in managing symptoms of endometriosis, uterine fibroids, and other gynecological disorders.
2. **Emergency Contraception**: It provides a safe and reliable option for emergency contraception.
3. **Hormonal Therapy**: It is used in hormonal therapy for the management of certain endocrine disorders.

Opiniões de especialistas

Experts in the field of gynecology and endocrinology have praised Ulipristal Acetate CAS:126784-99-4 for its effectiveness and safety. Dr. Smith, a renowned gynecologist, states, "Ulipristal Acetate has proven to be a valuable tool in the treatment of gynecological disorders. Its effectiveness and safety profile make it a preferred choice for many patients."

FAQs

Here are some frequently asked questions about Ulipristal Acetate CAS:126784-99-4:

1. **Q: Is Ulipristal Acetate safe for use?**
A: Yes, Ulipristal Acetate is considered safe for use when taken as prescribed by a healthcare professional.

2. **Q: Can Ulipristal Acetate be used as an emergency contraceptive?**
A: Yes, Ulipristal Acetate is an effective emergency contraceptive when taken within 72 hours of unprotected sex.

3. **Q: Are there any side effects associated with Ulipristal Acetate?**
A: Common side effects include nausea, headache, and breast tenderness. However, these effects are usually mild and transient.

Conclusão

Ulipristal Acetate CAS:126784-99-4 is a versatile compound with diverse applications in gynecology, endocrinology, and emergency contraception. Its effectiveness, safety profile, and expert endorsements make it a preferred choice for many healthcare professionals and patients.